domenica, 16 giugno 2024
20 Dicembre 2016

Frontline Pembrolizumab Receives Positive CHMP Opinion for PD-L1+

16 Dicembre 2016 – The Committee for Medicinal Products for Human Use (CHMP) has recommended approval of frontline pembrolizumab for the treatment of patients with metastatic non–small cell lung cancer whose tumors do not harbor EGFR or ALK mutations. The application, which is specifically for patients with PD-L1 expression levels ≥50%, is based on data from phase III KEYNOTE-024 trial, in which single-agent pembrolizumab reduced the risk of death by 40% and … (leggi tutto)